- Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of ...Endpoints · 2mo ago↗ source
- Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prepCapricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…Endpoints · 2mo ago↗ source
- Odyssey raises more than $300M as biotech goes publicOdyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The b…